Optima Coil Performance in The Interventional Management of Intracranial Aneurysms Registry
This is a prospective, open-label, consecutive enrollment, multi-center, U.S. registry of patients with intracranial aneurysms who are treated with the Optima Coil System. The primary objective of this registry is to evaluate the safety and effectiveness of the OptimaTM Coil System, including the OptiMAX Coils, in the real-world treatment of intracranial aneurysms. Imaging will be analyzed by a designated core neuroimaging lab to assess procedural success and aneurysm occlusion rates. Intent to treat population total: 700 patients 600 patients, up to 100 screen failures.
⁃ Patients enrolled in this registry must be treated in accordance with the FDA-cleared indication for the Optima Coil System.
⁃ In addition:
• Patient age ≥ 18 years;
• Candidate aneurysm is a previously untreated, saccular intracranial aneurysm measuring ≤ 24 mm in maximal diameter and suitable for embolization with coils;
• OptimaTM coil system accounts for at least 75% of the total number of implanted coils;
• Patient/ LARreceived the IRB-approved Consent Information Sheet to augment clinical procedure consent, and provided verbal consent to participate in the study
• Subject willing to comply with the protocol follow-up requirements; and
• Hunt \& Hess classification of equal to or less than 4 for ruptured aneurysms, if applicable.